Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis

GRADE guidelines: 22. The GRADE approach for tests and strategies—from test accuracy to patient-important outcomes and recommendations

(2019) Holger J. Schünemann et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy

(2019) Natalia N. Nalivaeva et al.   BRITISH JOURNAL OF PHARMACOLOGY

Intravenous immunoglobulins for Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease: A systematic review with meta-analysis

(2019) Jia Liu et al.   Expert Review of Neurotherapeutics

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

(2018) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease

(2018) Manuel Menendez-Gonzalez et al.   Frontiers in Aging Neuroscience

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

β-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View

(2017) Botond Penke et al.   MOLECULES

A phase 3 trial of IV immunoglobulin for Alzheimer disease

(2017) Norman R. Relkin et al.   NEUROLOGY

Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis

(2017) Jia-Jie Mo et al.   Annals of Clinical and Translational Neurology

Assessing small study effects and publication bias in orthodontic meta-analyses: a meta-epidemiological study

(2014) Spyridon N. Papageorgiou et al.   Clinical Oral Investigations

Increased CSF APPs-  levels in patients with Alzheimer disease treated with acitretin

(2014) K. Endres et al.   NEUROLOGY

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neuropathological Alterations in Alzheimer Disease

(2013) A. Serrano-Pozo et al.   Cold Spring Harbor Perspectives in Medicine

Meta-regression approximations to reduce publication selection bias

(2013) T. D. Stanley et al.   Research Synthesis Methods

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

What is the clinically relevant change on the ADAS-Cog?

(2011) Anette Schrag et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Determining the minimum clinically important differences for outcomes in the DOMINO trial

(2010) Robert Howard et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial

(2008) Holger Kessler et al.   JOURNAL OF NEURAL TRANSMISSION